Chronic Lymphocytic Leukaemia Laboratory, Institut Pasteur de Montevideo, Montevideo, Uruguay.
Department of Developmental Neurobiology, Instituto de Investigaciones Biologicas Clemente Estable, Montevideo, Uruguay.
Br J Haematol. 2018 Aug;182(4):521-525. doi: 10.1111/bjh.15427. Epub 2018 Jun 28.
Lipoprotein lipase (LPL) mRNA expression in chronic lymphocytic leukaemia (CLL) is associated with an unmutated immunoglobulin profile and poor clinical outcome. We evaluated the subcellular localization of LPL protein in CLL cells that did or did not express LPL mRNA. Our results show that LPL protein is differently located in CLL cells depending on whether it is incorporated from the extracellular medium in mutated CLL or generated de novo by leukaemic cells of unmutated patients. The specific quantification of endogenous LPL protein correlates with mRNA expression levels and mutational IGHV status, suggesting LPL protein as a possible reliable prognostic marker in CLL.
脂蛋白脂肪酶(LPL)mRNA 在慢性淋巴细胞白血病(CLL)中的表达与未突变的免疫球蛋白谱和不良临床结局相关。我们评估了 CLL 细胞中 LPL 蛋白的亚细胞定位,这些细胞表达或不表达 LPL mRNA。我们的结果表明,LPL 蛋白在 CLL 细胞中的定位不同,这取决于它是从突变的 CLL 细胞的细胞外介质中摄取的,还是由未突变患者的白血病细胞从头生成的。内源性 LPL 蛋白的特异性定量与 mRNA 表达水平和 IGHV 突变状态相关,提示 LPL 蛋白可能是 CLL 中一种可靠的预后标志物。